Brief reportElectronic monitoring of antipsychotic medication adherence in outpatients with schizophrenia or schizoaffective disorder: An empirical evaluation of its reliability and predictive validity
Introduction
Assessing the medication adherence of outpatients with schizophrenia or schizoaffective disorder is a major challenge. Clinicians generally rely on patients' self-report of adherence. Clinical researchers have used various adherence assessment methods, and each method has its own critical shortcomings (Osterberg and Blaschke, 2005).
Electronic monitoring (EM) has become increasingly used to assess medication adherence in general medical and schizophrenia populations (Byerly et al., 2005a, Byerly et al., 2005b, Diaz et al., 2001, Diaz et al., 2004, Osterberg and Blaschke, 2005). The most commonly employed EM device consists of a medication vial cap that has the same appearance as regular medication bottle caps, but electronically records the date and time of bottle opening. Although EM is increasingly used in outpatients with mental disorders, its reliability and predictive validity have not been fully evaluated in these populations. Accordingly, this study examined the reliability and predictive validity of EM in outpatients with schizophrenia or schizoaffective disorder.
Section snippets
Participants
Sixty-one adult outpatients diagnosed with schizophrenia (n = 35) or schizoaffective disorder (n = 26), as established by the Structured Clinical Interview for DSM-IV, were recruited from three Dallas County public mental health outpatient clinics. Most participants were self-referred from flyers (a few being referred by their treating clinician). Participants were recruited and studied at their usual outpatient clinics. Participants were taking a single oral antipsychotic, and they were at least
Participant characteristics
The study sample included 30 males (49.2%) and 31 females (50.8%), with an average age of 44.3 years, S.D. = 9.1 (range 21–59 years). The average age at illness onset was 23.1 years (S.D. = 10.1). Participants included 40 (65.6%) African Americans, 19 (31.2%) Caucasians, and 2 (3.2%) Hispanics. Twenty-four (39.3%) participants had less than a high school education and 37 (60.7%) had at least a high school education. Forty-three (70.5%) participants did not have a caregiver. The average baseline
Discussion
The current study examined the reliability and predictive validity of EM to assess the oral antipsychotic medication adherence of outpatients with schizophrenia or schizoaffective disorder. The internal reliability of EM to track (over time) oral antipsychotic medication adherence was excellent (α = 0.94 across the entire 6-month study period). The various initial EM assessment periods each had excellent agreement with the subsequent EM assessment periods. Both reliability analyses indicated that
Acknowledgements
This study was supported by NIMH K-Award grant # 5 K23 MH064930, the Stanley Medical Research Institute, the Betty Jo Hay Distinguished Chair in Mental Health, and by a grant from Janssen Medical Affairs, LLC.
References (11)
- et al.
A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia
Psychiatry Research
(2005) - et al.
Indicators of medication compliance in first-episode psychosis
Psychiatry Research
(2002) - et al.
Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions
Journal of Hypertension
(2001) - et al.
A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder
Journal of Clinical Psychiatry
(2005) - et al.
Use of the medication event monitoring system to estimate medication compliance in patients with schizophrenia
Journal of Psychiatry & Neuroscience
(2001)
Cited by (37)
Antipsychotic nonadherence measured by electronic adherence monitoring in stabilized chronic schizophrenia: Clinical implications
2021, Schizophrenia ResearchCitation Excerpt :From this perspective, it would be valuable to look at not only studies examining the association of adherence with illness/symptom severity at endpoint but also studies examining the same with illness/symptom severity at baseline. To our knowledge, there have been 6 studies looking at overall adherence and endpoint severity (Acosta et al., 2014, 2013; Brain et al., 2013; Remington et al., 2013, 2007; Yang et al., 2012) and 3 studies looking at adherence and severity at multiple points (Diaz et al., 2001; Nakonezny et al., 2008; Subotnik et al., 2014), respectively; all studies showed that poor adherence was significantly associated with worse illness/symptom severity. However, no study has looked at overall adherence and both baseline and endpoint severity.
Digital Biomarkers in Clinical Drug Development
2019, Handbook of Behavioral NeuroscienceCitation Excerpt :Smart wireless pill bottles can help identify and improve medication adherence. Medication vial cap devices are currently being used by patients in the pharmaceutical and research environments to collect and store all adherence data and have become common practice in general medicine (Byerly et al., 2005; Byerly, Nakonezny, & Lescouflair, 2007; Diaz, Neuse, Sullivan, Pearsall, & Woods, 2004; Nakonezny, Byerly, & Rush, 2008; Osterberg & Blaschke, 2005). The data are also readily accessible to physicians in real time.
Measuring adherence to antipsychotic medications for schizophrenia: Concordance and validity among a community sample in rural China
2018, Schizophrenia ResearchCitation Excerpt :Structured and standardized scales have been developed to improve patient interviews and self-reports, including the Brief Adherence Rating Scale (BARS) (Byerly et al., 2008), the Medication Adherence Rating Scale (MARS) (Fialko et al., 2008), the Brief Evaluation of Medication Influences and Beliefs (BEMIB) (Dolder et al., 2004), and the Drug Attitude Inventory (DAI) (Awad, 1993). As a presumably more objective measure electronic monitoring via a microchip-imbedded cap to capture each pill bottle opening appeared in the literature during the 1980s (Cramer et al., 1989; Spector et al., 1986) and has been used increasingly in addition to pill counts (Cramer and Rosenheck, 1999; Nakonezny et al., 2008). Despite advances in measurement methodologies, there has been scant research examining the concordance among measures of adherence to antipsychotics or appraisal of their validity versus a reference standard.
Evaluation of adherence patterns in schizophrenia using electronic monitoring (MEMS®): A six-month post-discharge prospective study
2018, Schizophrenia ResearchCitation Excerpt :While factors associated with medication non-adherence are known, the identification of patients with poor adherence remains an important challenge in clinical practice (Misdrahi et al., 2016). Most prior studies investigating medication adherence, however, have relied on subjective or indirect methods such as self-reports, provider-reports, or chart reviews to assess adherence (Nakonezny et al., 2008; Osterberg and Blaschke, 2005; Velligan et al., 2006). Electronic medication event monitoring is regarded as the most reliable measure of adherence (Chesney, 2006; Velligan et al., 2009).
Twelve months of electronic monitoring (MEMS<sup>®</sup>) in the Swedish COAST-study: A comparison of methods for the measurement of adherence in schizophrenia
2014, European NeuropsychopharmacologyCitation Excerpt :The MEMS® has a medication bottle cap equipped with a microprocessor that records the occurrence and time of each bottle opening. The reliability and predictive validity for MEMS® has been shown to be high (Nakonezny et al., 2008). However, the MEMS® approach has its drawbacks as it requires regular monitorings and the technique cannot detect pill discarding (Farmer, 1999; Goff et al., 2010).